TOKYO -- Japanese drugmaker Eisai said Wednesday it will invest up to $15 million in C2N Diagnostics, a U.S. biotechnology firm that has developed a blood test for early signs of Alzheimer's disease.
C2N's diagnostic assay can detect amyloid beta -- a type of protein fragment that form plaques in the brain linked to Alzheimer's -- in a small quantity of blood.
